Description
Product Description
Cagrilintide + Semaglutide is a dual-peptide research compound combining two well-characterized metabolic signaling peptides frequently investigated in studies of energy balance and glucose homeostasis.
Cagrilintide is a long-acting amylin analogue engineered to enhance receptor stability and prolong biological activity. Amylin is a pancreatic peptide hormone co-secreted with insulin and plays an important role in satiety signaling, gastric emptying modulation, and postprandial metabolic regulation.
Semaglutide is a GLP-1 receptor agonist peptide known for its extended half-life and high receptor affinity. It is widely investigated in research examining incretin signaling, insulin secretion dynamics, and appetite-related pathways.
The co-administration of Cagrilintide and Semaglutide has become an area of significant scientific interest because the amylin and GLP-1 pathways operate through complementary mechanisms within the central nervous system and gastrointestinal system. Preclinical and clinical research suggests that simultaneous activation of these pathways may produce enhanced metabolic signaling responses compared with single-pathway modulation.
This 2.5mg + 2.5mg lyophilized peptide formulation is manufactured with ≥99% purity, verified through analytical techniques such as HPLC and mass spectrometry, ensuring suitability for advanced biochemical and pharmacological research environments.

Product Specifications
| Specification | Details |
|---|---|
| Product Name | Cagrilintide 2.5mg + Semaglutide 2.5mg |
| Synonyms | AM833 + Semaglutide Combination |
| CAS Number | Not officially assigned (combination product) |
| Molecular Formula | Combination peptide formulation |
| Molecular Weight | Cagrilintide: ~3964 Da / Semaglutide: ~4113 Da |
| Amino Acid Sequence | Cagrilintide and Semaglutide proprietary peptide sequences |
| Peptide Type | Amylin analogue + GLP-1 receptor agonist |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Strength Options | 2.5mg + 2.5mg |
| Appearance | White to off-white sterile lyophilized powder |
| Identity Verification | HPLC, Mass Spectrometry |
| Solubility | Soluble in sterile water or research-grade buffer solutions |
| Packaging | Sterile research vials |
| Storage Condition | Store at −20°C to −80°C, protected from light |
| Intended Use | Research use only. Not for human or veterinary use. |
Applications
The Cagrilintide + Semaglutide peptide combination is frequently investigated in metabolic and endocrine research settings.
Metabolic Regulation Studies
Researchers explore this peptide pair to examine integrated appetite regulation mechanisms, particularly those involving hypothalamic satiety signaling and gut-brain hormonal communication.
Obesity and Energy Balance Research
Dual activation of amylin and GLP-1 pathways allows scientists to study potential synergistic effects on energy intake, body weight regulation, and adipose tissue signaling.
Glucose Metabolism Models
Semaglutide’s incretin activity combined with Cagrilintide’s satiety signaling makes this formulation valuable in studies examining glucose tolerance, insulin dynamics, and metabolic homeostasis.
Neuroendocrine Signaling
The peptides influence central appetite control circuits, particularly within the hypothalamus and brainstem. Researchers often investigate neuronal activation markers and signaling cascades in these regions.
Gastrointestinal Motility Research
Both peptides can affect gastric emptying and digestive hormone release, making them useful for studies of gastrointestinal endocrine responses.
Key Research Advantages
Dual-pathway metabolic signaling model
≥99% verified peptide purity
Stable lyophilized formulation
High batch consistency suitable for controlled experiments
Widely investigated amylin–GLP-1 pathway combination
Contact & Bulk Supply
For factory wholesale pricing, bulk quantities, and technical documentation (COA, HPLC reports, MS analysis), please contact our technical sales team for detailed product information and availability.
Scientific References
The following scientific publications provide authoritative information about the mechanisms and research interest surrounding amylin analogues and GLP-1 receptor agonists.
National Center for Biotechnology Information – Amylin receptor agonists and metabolic regulation
https://www.ncbi.nlm.nih.gov/PubMed – Research publications related to Cagrilintide and GLP-1 receptor agonists
https://pubmed.ncbi.nlm.nih.gov/The New England Journal of Medicine – Clinical and translational research on incretin-based therapies
https://www.nejm.org/Nature – Reviews on metabolic signaling and peptide therapeutics
https://www.nature.com/ClinicalTrials.gov – Ongoing and completed studies involving amylin and GLP-1 pathway modulation
https://clinicaltrials.gov/





Reviews
There are no reviews yet.